33 related articles for article (PubMed ID: 15919490)
1. Effects of cyclosporine-tacrolimus switching in posttransplantation hyperlipidemia on high-density lipoprotein 2/3, lipoprotein a1/b, and other lipid parameters.
Seymen P; Yildiz M; Türkmen MF; Titiz MI; Seymen HO
Transplant Proc; 2009 Dec; 41(10):4181-3. PubMed ID: 20005364
[TBL] [Abstract][Full Text] [Related]
2. Tacrolimus conversion improves hyperlipidemic states in stable liver transplant recipients.
Manzarbeitia C; Reich DJ; Rothstein KD; Braitman LE; Levin S; Munoz SJ
Liver Transpl; 2001 Feb; 7(2):93-9. PubMed ID: 11172391
[TBL] [Abstract][Full Text] [Related]
3. Do blood pressure and arterial wall properties change after conversion from cyclosporine to tacrolimus?
Gelens MA; Christiaans MH; v Hooff JP
Transplant Proc; 2005 May; 37(4):1900-1. PubMed ID: 15919498
[TBL] [Abstract][Full Text] [Related]
4. New onset dyslipidemia after renal transplantation: is there a difference between tacrolimus and cyclosporine?
Deleuze S; Garrigue V; Delmas S; Chong G; Swarcz I; Cristol JP; Mourad G
Transplant Proc; 2006 Sep; 38(7):2311-3. PubMed ID: 16980075
[TBL] [Abstract][Full Text] [Related]
5. Open prospective multicenter study of conversion to tacrolimus therapy in renal transplant patients experiencing ciclosporin-related side-effects.
Margreiter R; Pohanka E; Sparacino V; Sperschneider H; Kunzendorf U; Huber W; Lameire N; Andreucci VE; Donati D; Heemann U;
Transpl Int; 2005 Jul; 18(7):816-23. PubMed ID: 15948861
[TBL] [Abstract][Full Text] [Related]
6. Improved attainment of NKF classified lipid target levels after conversion from cyclosporine to tacrolimus in renal graft recipients.
Pohanka E; Margreiter R; Sparacino V; Sperschneider H;
Transplant Proc; 2005 May; 37(4):1874-6. PubMed ID: 15919490
[TBL] [Abstract][Full Text] [Related]
7. Assessing the relative risk of cardiovascular disease among renal transplant patients receiving tacrolimus or cyclosporine.
Jardine AG
Transpl Int; 2005 Apr; 18(4):379-84. PubMed ID: 15773954
[TBL] [Abstract][Full Text] [Related]
8. Overview of tacrolimus-based immunosuppression after heart or lung transplantation.
Reichenspurner H
J Heart Lung Transplant; 2005 Feb; 24(2):119-30. PubMed ID: 15701425
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of antilipidemic therapies in chronic renal allograft failure.
Wanner C; Bartens W; Galle J
Kidney Int Suppl; 1995 Dec; 52():S60-2. PubMed ID: 8587286
[TBL] [Abstract][Full Text] [Related]
10. The metabolic effects of cyclosporin and tacrolimus.
Marchetti P; Navalesi R
J Endocrinol Invest; 2000; 23(7):482-90. PubMed ID: 11005276
[TBL] [Abstract][Full Text] [Related]
11. [Effect of immunosuppressants on lipids].
Pouteil-Noble C; Guebre F
Nephrologie; 2000; 21(7):369-72. PubMed ID: 11200615
[No Abstract] [Full Text] [Related]
12. Impact of immunosuppressive therapy on hypertension.
MacDonald AS
Transplantation; 2000 Dec; 70(11 Suppl):SS70-6. PubMed ID: 11152235
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
